ישראל - עברית - Ministry of Health

teva israel ltd - metformin hydrochloride; sitagliptin as malate - טבליות מצופות פילם - metformin hydrochloride 1000 mg; sitagliptin as malate 50 mg - metformin and sitagliptin

ישראל - עברית - Ministry of Health

teva israel ltd - metformin hydrochloride; sitagliptin as malate - טבליות מצופות פילם - metformin hydrochloride 500 mg; sitagliptin as malate 50 mg - metformin and sitagliptin

ישראל - עברית - Ministry of Health

teva israel ltd - metformin hydrochloride; sitagliptin as malate - טבליות מצופות פילם - metformin hydrochloride 850 mg; sitagliptin as malate 50 mg - metformin and sitagliptin

ישראל - עברית - Ministry of Health

teva israel ltd - metformin hydrochloride; sitagliptin as phosphate - טבליות מצופות פילם - sitagliptin as phosphate 50 mg; metformin hydrochloride 1000 mg - metformin

ישראל - עברית - Ministry of Health

teva israel ltd - metformin hydrochloride; sitagliptin as phosphate - טבליות מצופות פילם - sitagliptin as phosphate 50 mg; metformin hydrochloride 500 mg - metformin

ישראל - עברית - Ministry of Health

novartis pharma services ag - metformin hydrochloride 850 mg; vildagliptin 50 mg - film coated tablets - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus:• eucreas is indicated in the treatment of type 2 diabetes patients who are unable to achieve sufficient glycemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.• eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea.• eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

ישראל - עברית - Ministry of Health

novartis pharma services ag - metformin hydrochloride 500 mg; vildagliptin 50 mg - film coated tablets - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - metformin hydrochloride 1000 mg; sitagliptin as monohydrate phosphate 50 mg - tablets - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - metformin hydrochloride 1000 mg; sitagliptin as monohydrate phosphate 50 mg - tablets - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - metformin hydrochloride 1000 mg; sitagliptin as monohydrate phosphate 50 mg - tablets - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.